Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
16.51
+0.11 (0.67%)
At close: Dec 5, 2025, 4:00 PM EST
16.44
-0.07 (-0.42%)
After-hours: Dec 5, 2025, 7:48 PM EST

Janux Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Revenue
1010.598.088.613.64-
Upgrade
Revenue Growth (YoY)
-23.37%30.99%-6.14%136.79%--
Upgrade
Cost of Revenue
76.2668.3954.9253.4426.243.04
Upgrade
Gross Profit
-66.26-57.8-46.84-44.83-22.6-3.04
Upgrade
Selling, General & Admin
39.1341.0526.1422.2610.331.8
Upgrade
Research & Development
38.9-----
Upgrade
Operating Expenses
78.0341.0526.1422.2610.331.8
Upgrade
Operating Income
-144.29-98.85-72.98-67.09-32.93-4.84
Upgrade
Interest Expense
------0.21
Upgrade
Interest & Investment Income
42.3929.8514.694.030.26-
Upgrade
EBT Excluding Unusual Items
-101.9-68.99-58.29-63.06-32.67-5.05
Upgrade
Other Unusual Items
------1.74
Upgrade
Pretax Income
-101.9-68.99-58.29-63.06-32.67-6.78
Upgrade
Net Income
-101.9-68.99-58.29-63.06-32.67-6.78
Upgrade
Net Income to Common
-101.9-68.99-58.29-63.06-32.67-6.78
Upgrade
Shares Outstanding (Basic)
61544441241
Upgrade
Shares Outstanding (Diluted)
61544441241
Upgrade
Shares Change (YoY)
18.41%22.12%6.14%76.24%2471.20%36.71%
Upgrade
EPS (Basic)
-1.68-1.28-1.32-1.52-1.39-7.41
Upgrade
EPS (Diluted)
-1.68-1.28-1.32-1.52-1.39-7.41
Upgrade
Free Cash Flow
-71.4-44.17-52.43-49.37-18.46-4.37
Upgrade
Free Cash Flow Per Share
-1.18-0.82-1.19-1.19-0.78-4.77
Upgrade
Operating Margin
-1442.88%-933.58%-902.87%-779.04%-905.39%-
Upgrade
Profit Margin
-1018.95%-651.62%-721.18%-732.22%-898.32%-
Upgrade
Free Cash Flow Margin
-713.97%-417.20%-648.58%-573.24%-507.51%-
Upgrade
EBITDA
-142.22-96.79-71.02-66.25-32.82-4.83
Upgrade
D&A For EBITDA
2.072.061.960.840.110.01
Upgrade
EBIT
-144.29-98.85-72.98-67.09-32.93-4.84
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.